Background Little is known on the actual diagnostic and therapeutic management of recurrent miscarriage and the impact of introducing guidelines on this topic.
Introduction
The incidence of recurrent miscarriage among couples trying to conceive is 1-3%. A causal factor can be identified in only half of these couples.
1,2 Primary antiphospholipid syndrome and structural chromosomal abnormalities are factors in which the causal relationship with recurrent miscarriage is the most evident. 3 Other risk factors are endocrine factors, uterine anomalies, thrombophilia and smoking. However, a proven effective therapy exists only in the case of antiphospholipid syndrome. 3 The Dutch guideline 'Recurrent Miscarriage' was introduced in 1999. 4 Before the introduction of this guideline, a survey among Dutch gynaecologists demonstrated that no consensus existed on the definition and management of recurrent miscarriage and that diagnostic testing for factors without therapeutic consequences was performed frequently. 5 Recently, many reports have been published, discussing the importance of evidence-based medicine in relation to recurrent miscarriage. [3] [4] [5] [6] [7] However, little is known on the actual diagnostic and therapeutic management of recurrent miscarriage and the impact of introducing guidelines on this topic.
To evaluate any changes in the management of recurrent miscarriage after the introduction of the guideline, we conducted a second survey among Dutch gynaecologists.
Materials and methods
A questionnaire was sent to all 101 practices for obstetrics and gynaecology in
The Netherlands in July 2003. Eight of these practices were located in university hospitals, 36 practices in non-university teaching hospitals and 57 practices in non-teaching hospitals. The questionnaire consisted mainly of multiple choice questions, with the possibility to elucidate the answers. The questions dealt with the definition of recurrent miscarriage, risk factors and diagnostic testing and therapy in couples with recurrent miscarriage. Gynaecologists were asked to indicate which factors they considered as risk factors, which diagnostic tests they ordered on a routine basis and which on a specific indication and which interventions were applied to prevent future miscarriages.
The data were compared with the results of the first survey conducted before the introduction of the guideline and with the recommendations made in the guideline 'Recurrent Miscarriage'. 4 The percentages in the tables are based on the total number of respondents who answered the questions.
Results
Completed questionnaires were returned by 84/101 (83%) of the practices, among which 7/8 (88%) were from university hospitals, 31/36 (86%) from nonuniversity teaching hospitals and 46/57 (81%) from non-teaching hospitals. Two practices refused to participate and 15 practices did not respond.
In total, 74/77 (96%) of the respondents answered that a protocol for the management of recurrent miscarriage existed in their clinic, compared with 42% before the introduction of the guideline.
Definition
In the Dutch guideline, recurrent miscarriage is defined as three or more consecutive pregnancy losses, with a gestational age up to 22 weeks. This cut-off value for gestational age was applied by only 2/76 (3%) respondents, whereas 78% of the respondents used a maximal gestational age of [15] [16] weeks, 12% a gestational age of 9 weeks and 1% used a different value.
Before the introduction of the guideline, the cut-off value was similar: 71% of the respondents used a gestational age of 16-17 weeks, whereas the other respondents did not clarify this item at that time. 'Recurrent miscarriage' was defined as 3 or more miscarriages by 60/77 (78%) respondents and 2 or more by 22% of the respondents. Before the introduction of the guideline, this was similar (71% and 29%, respectively). For 50% of the respondents, it was essential that the recurrent miscarriage had occurred in consecutive pregnancies. For the other respondents, this was irrespective of the outcome of interspersing pregnancies.
The recurrent miscarriage had to occur with the same partner for 29/73 (40%) of the respondents, and for 60% of the respondents this was irrespective of the partner(s). Before the introduction of the guideline, these percentages were 34%
and 46%, respectively. The remaining respondents had no opinion regarding this specific item.
Risk factors
Risk factors for recurrent miscarriage according to the respondents as well as the guidelines point of view are listed in Table I . In the previous survey, before the introduction of the guideline, this topic was not investigated. Although thyroid gland dysfunction and infections are not risk factors according to the guideline, 42% and 27%, respectively, of the respondents regarded them as such. On the other hand, a high LH level and/ or polycystic ovary disease are regarded as risk factors in the guideline, whereas they were not by 52% and 36%, respectively, of the respondents. 
Diagnostic testing
Tests applied in the case of recurrent miscarriage are listed in Table II . In the Dutch guideline, it is recommended that parental chromosome analysis be performed after two (or more) miscarriages and other tests only after three (or more). Almost all respondents (96-98%) claimed to have performed parental chromosome analysis in couples with recurrent miscarriage, compared with 78% before the introduction of the guideline. Parental chromosome analysis was offered after 2 miscarriages by 63/77 (82%) respondents and after 3 by 18% of the respondents. Other diagnostic tests were applied after 2 miscarriages by 24/76 (32%) respondents and after 3 by 52/76 (68%) respondents. In the Dutch guideline, hysterosalpingography or hysteroscopy is advised on a specific indication. However, to examine the uterine cavity, 4% of the respondents reported to have performed saline-infusion sonography on a routine basis and 32% only on a specific indication. Using this technique, the uterine cavity is examined sonographically while saline is infused in the uterus. In the Dutch guideline, this rather new technique is not yet mentioned.
Tests for endocrine abnormalities were claimed to be performed frequently before as well as after the introduction of the guideline. Besides examining LH/FSH and plasma glucose on indication, this is not recommended in the Dutch guideline.
Many of the respondents routinely screened for antiphospholipid syndrome.
Testing for other thrombophilia factors is also performed more frequently after the introduction of the guideline. In particular, protein C (75% versus 31%), protein S (74% versus 30%), antithrombin III (62% versus 23%) and factor V Leiden (65% versus 12%) are investigated on a routine basis. In the Dutch guideline, this is recommended only on a specific indication. Activated protein C resistance was performed as a routine test by 73% of the respondents after the introduction of the guideline. This item was not included in the questionnaire in 1996. Other tests were also ordered on a routine basis, whereas in the guideline, they are advised only on a specific indication; for example, APTT, DRVVT and prenatal diagnosis in the case of structural chromosome abnormalities.
Testing for infections was still applied, although by less respondents, whereas in the guideline, it is stated that this is not indicated. Immunological testing was no longer performed after the introduction of the guideline. Ultrasound examination in early pregnancy was performed frequently before as well as after the introduction of the guideline (85% and 83%, respectively), even though it is not mentioned in the guideline. 
Therapy
Therapeutic interventions performed to prevent further miscarriage are listed in Table III . After the introduction of the guideline, more respondents advised to stop smoking (80% compared with 46%) and prescribed folic acid (85% compared with 53%). Furthermore, more respondents claimed to correct uterine anomalies (uterine septum resection 74% compared with 23%, myomectomy 79% compared with 39%, cerclage 43% compared with 18%), even though this is not recommended in the guideline. Fewer respondents prescribed progesterone (13% compared with 28%) and HCG (7% compared with 21%). After the introduction of the guideline, more respondents prescribed anticoagulants;
aspirin 51% compared with 27% and heparin 45% compared with 9%. In total, 57% of the respondents reported to prescribe aspirin in combination with heparin to prevent further recurrent miscarriage. In 1996, this item was not mentioned in the questionnaire.
Donor insemination and oocyte donation are not mentioned in the guideline, whereas 37% and 35%, respectively, of the respondents reported to apply these interventions. 
Discussion
The existence of a previous survey on the definition and management of recurrent miscarriage enabled us to compare its management before and after the introduction of the Dutch guideline in 1999 and thereby to evaluate its impact. We demonstrated that the adherence to the guideline is rather poor.
Even though the introduction of the guideline 'Recurrent Miscarriage' resulted in more structural testing for antiphospholipid syndrome, and aspirin and heparin were prescribed more frequently, many tests not recommended in the guideline were still applied and ineffective therapy was offered frequently. The high response rate (83%) suggests that the results of this study are representative for the management of recurrent miscarriage in The Netherlands.
Since 2004, the Dutch Society of Obstetrics and Gynaecology has explicit instructions for developing guidelines on the basis of the criteria of the Appraisal of Guidelines, Research and Evaluation in Europe (AGREE) instrument. 8 However,
in 1999, at the time the guideline 'Recurrent Miscarriage' was developed, these instructions were not as detailed. The guideline was developed by experts in the field. The concept was discussed by a guideline committee, after which it was put to the vote and approved by the members of the Dutch Society of Obstetrics and Gynaecology. After approval, it was published on the Society's website and a paper version was sent to the members. The validity of the guidelines expires after 5 years, and the present guideline is under revision.
The reasons for not following a guideline can be diverse. Barriers to guideline adherence can be guideline related (the guideline can be outdated, difficult to use or items can be controversial), physician related (for instance, lack of awareness or agreement), patient related (resistance to guideline recommendations) or related to environmental factors (for instance, lack of a reminder system or counselling materials). 9 In The Netherlands, in the field of Reproductive Medicine, it has been reported that adherence to the guideline on intrauterine insemination was mainly impeded by the physician's lack of self-efficacy and low-outcome expectancy. 10 Reasons for not following the Dutch guideline 'Recurrent Miscarriage' may be guideline related. To make good guidelines on the topic of recurrent miscarriage is extremely difficult. Many aetiological factors, tests and treatments for recurrent miscarriage are still controversial. 3, 6 In 2003, at the time this survey was conducted, new data had become available, requiring a different approach. For instance, in the guideline, alcohol consumption is considered a questionable risk for recurrent miscarriage, but a later study documented that alcohol consumption during pregnancy strongly increases its risk. 11 Elevated LH levels are considered risk factors for recurrent miscarriage in the guideline, but later studies could not confirm this. 12, 13 In the guideline, testing for the antiphospholipid syndrome is recommended on a specific indication, whereas after the development of the guideline, international consensus was reached on the usefulness of routine testing. 14 In the guideline, ultrasound examination is recommended to detect intracavitary uterine anomalies, whereas later it was demonstrated that salineinfusion sonography is a much more sensitive and specific investigation for this purpose. 15 The guideline may also be confusing or difficult to use. The definition of recurrent miscarriage according to the Dutch guideline is seldom followed.
Lack of international consensus on a definition may be a contributing factor in this respect. 3, 16 In the Dutch guideline, it is recommended that parental chromosome analysis be performed after two miscarriages and the remaining tests after three.
In The Netherlands, for convenience, this might result in performing the complete workups after two miscarriages. In most other countries, the complete workup is recommended after three miscarriages.
Other reasons for not following the guideline seem to be physician related rather than guideline related. For example, testing serum glucose without clinical manifestation of diabetes is not effective. 17 Many tests were performed on a routine basis, even though it is advised to perform these tests only in the presence of a specific indication, for example, testing for thrombophilia. After the introduction of the guideline, more gynaecologists reported to correct uterine anomalies to prevent recurrent miscarriage, even though no convincing evidence exists on its effectiveness. 18 This is also the case for artificial insemination with donor semen and for oocyte donation. Ultrasound examination in early pregnancy was frequently performed even without clinical implications. Justification for doing so may, however, be to reassure the patient in the case of an ongoing pregnancy. 19 
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The data of this study indicate that physicians and/or patients apparently wish to initiate treatment for recurrent miscarriage, even if the effectiveness has not been established or has proved to be ineffective. On the other hand, if there is a physicians' lack of awareness of the guideline, this may be due to poor advertisement and dissemination to interested parties. Successful implementation of the guideline requires more interventions than distribution or (electronic) publication, such as educational meetings, local consensus processes, the employment of local opinion leaders and audit and feedback. 20 In the UK and Scandinavia, early pregnancy units exist with main focus on early pregnancy loss.
In The Netherlands and other European countries, these specialized units are not established so far. It could be expected that centralized care also leads to more consensus in management and better adherence to guidelines.
In conclusion, the adherence to the Dutch guideline 'Recurrent Miscarriage' is rather poor, presumably due to guideline-related as well as physician-related barriers. Too many diagnostic tests and ineffective therapeutic interventions are performed. This study demonstrates the importance of appropriate implementation and revision.
